Jennifer Kryskalla, PharmD; Shira Kern, MA; David Gray, PharmD; and Peter Hauser, MD
Dr. Kryskalla is the VISN 22 pharmacoeconomist and pharmacy data analyst, Ms. Kern is a clinical research coordinator, Dr. Gray is the VISN 22 pharmacy executive, and Dr. Hauser is the VISN 22 mental health care services lead. Dr. Kryskalla, Dr. Gray, and Dr. Hauser are at the Desert Pacific Veterans Integrated Service Network in Long Beach, California. Ms. Kern is at the VA Long Beach Healthcare System.
Acknowledgements The authors wish to thank the leadership of VISN 22 for their support of this initiative. Dr. Kryskalla recognizes VA OI&T for making this work possible and her family for their support. Ms. Kern would like to thank Aaron, Leslie, and Rachel Kern for their continuous support. Dr. Hauser wishes to thank Cathy, Anika, Katia, Max, and Jirina Hauser for their unwavering support.
Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.
Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
[Published Online Ahead of Print: August 14, 2014.]
